Somsupha Kanjanauthai, MD
Interventional Cardiology · Los Angeles, CANPI 1285843979
Payments from drug & device makers
Across 78 payments — averaging $210.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Boston Scientific$2K
- Penumbra, Inc.$1K
- Edwards Lifesciences$653
- Abiomed$560
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$311
- plus $288 from 7 others
What the payments were for
- Travel & lodging$13,34181%
- Food & beverage$3,06119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $11,236 |
| Boston Scientific | 16 | $2,102 |
| Penumbra, Inc. | 3 | $1,252 |
| Edwards Lifesciences | 10 | $653 |
| Abiomed | 11 | $560 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $311 |
| Cvrx, Inc. | 1 | $113 |
| Philips North America LLC | 2 | $52 |
| Abbott | 2 | $43 |
| Lantheus Medical Imaging, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 1 | $23 |
| Amgen | 1 | $19 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,402 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $12,068 |
| BrilintaTicagrelor | 15 | $9,300 |
| Atorvastatin Calcium | 88 | $664 |
| Bumetanide | 14 | $636 |
| Pantoprazole Sodium | 58 | $541 |
| ClopidogrelClopidogrel Bisulfate | 65 | $424 |
| Metoprolol Succinate | 41 | $309 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 11 | $218 |
| Furosemide | 33 | $128 |
| Lisinopril | 38 | $126 |
| Amlodipine Besylate | 40 | $123 |
| Carvedilol | 32 | $99 |
| Metoprolol Tartrate | 42 | $78 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$1.4M
- Ray MatthewsLos Angeles$653K
- Steven BursteinLos Angeles$514K
- Jubin JosephLos Angeles$312K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.